nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinolone Acetonide—PLA2G4A—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00789	0.0519	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Estradiol—Estropipate—osteoporosis	0.00744	0.418	CbGdCrCtD
Fluocinolone Acetonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—RAP1A—osteoporosis	0.00572	0.0376	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—TUBA1B—osteoporosis	0.00567	0.0373	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Estradiol—Conjugated Estrogens—osteoporosis	0.00564	0.317	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Estradiol—Ethinyl Estradiol—osteoporosis	0.00473	0.266	CbGdCrCtD
Fluocinolone Acetonide—PLA2G4A—Glycerophospholipid biosynthesis—MGLL—osteoporosis	0.00365	0.024	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—COL1A2—osteoporosis	0.00318	0.0209	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Ca-dependent events—ADCY5—osteoporosis	0.00296	0.0195	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—ALPL—osteoporosis	0.00287	0.0189	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—WDR1—osteoporosis	0.00278	0.0183	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Phospholipid metabolism—MGLL—osteoporosis	0.00255	0.0167	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—IRS2—osteoporosis	0.00235	0.0155	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—ESR2—osteoporosis	0.00234	0.0154	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—LEP—osteoporosis	0.0023	0.0151	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—CAP1—osteoporosis	0.0022	0.0145	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PLC beta mediated events—ADCY5—osteoporosis	0.00218	0.0143	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—G-protein mediated events—ADCY5—osteoporosis	0.00214	0.0141	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	0.00214	0.0141	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—COL1A2—osteoporosis	0.00207	0.0136	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—IRS1—osteoporosis	0.00205	0.0135	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—DKK1—osteoporosis	0.002	0.0131	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—NFATC1—osteoporosis	0.00197	0.0129	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Arachidonic acid metabolism—GPX1—osteoporosis	0.00196	0.0129	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—VDR—osteoporosis	0.00185	0.0122	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00185	0.0121	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	0.00184	0.0121	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—RAP1A—osteoporosis	0.00179	0.0118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—MGLL—osteoporosis	0.00175	0.0115	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—PTHLH—osteoporosis	0.00174	0.0114	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—NFATC1—osteoporosis	0.00173	0.0114	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Endothelins—ADCY5—osteoporosis	0.00164	0.0108	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—PLEK—osteoporosis	0.0016	0.0105	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Ibandronate—osteoporosis	0.00159	0.00192	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Etidronic acid—osteoporosis	0.00159	0.00191	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—AGER—osteoporosis	0.00158	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—BGLAP—osteoporosis	0.00158	0.0104	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Calcium Acetate—osteoporosis	0.00158	0.0019	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Estropipate—osteoporosis	0.00157	0.00189	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Risedronate—osteoporosis	0.00157	0.00189	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Pamidronate—osteoporosis	0.00157	0.00189	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Conjugated Estrogens—osteoporosis	0.00156	0.00188	CcSEcCtD
Fluocinolone Acetonide—Infestation—Conjugated Estrogens—osteoporosis	0.00156	0.00188	CcSEcCtD
Fluocinolone Acetonide—Cough—Raloxifene—osteoporosis	0.00156	0.00188	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Raloxifene—osteoporosis	0.00152	0.00183	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Ethinyl Estradiol—osteoporosis	0.00152	0.00183	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Risedronate—osteoporosis	0.00151	0.00182	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Ibandronate—osteoporosis	0.00151	0.00182	CcSEcCtD
Fluocinolone Acetonide—Oedema—Estropipate—osteoporosis	0.00151	0.00182	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Ethinyl Estradiol—osteoporosis	0.00151	0.00181	CcSEcCtD
Fluocinolone Acetonide—Infection—Estropipate—osteoporosis	0.0015	0.0018	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Ethinyl Estradiol—osteoporosis	0.0015	0.0018	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Pamidronate—osteoporosis	0.00149	0.00179	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Estropipate—osteoporosis	0.00148	0.00178	CcSEcCtD
Fluocinolone Acetonide—Infection—Alendronate—osteoporosis	0.00147	0.00178	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Risedronate—osteoporosis	0.00147	0.00177	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00147	0.00964	CbGpPWpGaD
Fluocinolone Acetonide—Sinusitis—Conjugated Estrogens—osteoporosis	0.00147	0.00176	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Risedronate—osteoporosis	0.00146	0.00176	CcSEcCtD
Fluocinolone Acetonide—Infection—Raloxifene—osteoporosis	0.00145	0.00175	CcSEcCtD
Fluocinolone Acetonide—Nasopharyngitis—Estradiol—osteoporosis	0.00145	0.00175	CcSEcCtD
Fluocinolone Acetonide—Back pain—Ethinyl Estradiol—osteoporosis	0.00145	0.00174	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Pamidronate—osteoporosis	0.00144	0.00173	CcSEcCtD
Fluocinolone Acetonide—Infection—Ibandronate—osteoporosis	0.00144	0.00173	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—WDR1—osteoporosis	0.00143	0.00943	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Raloxifene—osteoporosis	0.00143	0.00172	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Zoledronate—osteoporosis	0.00143	0.00172	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Ibandronate—osteoporosis	0.00142	0.00171	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—osteoporosis	0.00142	0.00932	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Nuclear Receptors—ESR1—osteoporosis	0.00142	0.00932	CbGpPWpGaD
Fluocinolone Acetonide—Back pain—Risedronate—osteoporosis	0.00141	0.0017	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Pamidronate—osteoporosis	0.00141	0.0017	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Conjugated Estrogens—osteoporosis	0.00141	0.00169	CcSEcCtD
Fluocinolone Acetonide—Influenza—Estradiol—osteoporosis	0.0014	0.00169	CcSEcCtD
Fluocinolone Acetonide—Nausea—Ergocalciferol—osteoporosis	0.00139	0.00168	CcSEcCtD
Fluocinolone Acetonide—Erythema—Pamidronate—osteoporosis	0.00139	0.00167	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Pamidronate—osteoporosis	0.00139	0.00167	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.00138	0.00906	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Estropipate—osteoporosis	0.00137	0.00165	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Zoledronate—osteoporosis	0.00136	0.00164	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Pamidronate—osteoporosis	0.00136	0.00164	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.00136	0.00893	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00135	0.00163	CcSEcCtD
Fluocinolone Acetonide—Visual impairment—Conjugated Estrogens—osteoporosis	0.00135	0.00163	CcSEcCtD
Fluocinolone Acetonide—Back pain—Pamidronate—osteoporosis	0.00134	0.00162	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—ADCY5—osteoporosis	0.00134	0.0088	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.00133	0.0016	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.00132	0.00159	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Zoledronate—osteoporosis	0.00131	0.00158	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Risedronate—osteoporosis	0.00131	0.00158	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Conjugated Estrogens—osteoporosis	0.00131	0.00158	CcSEcCtD
Fluocinolone Acetonide—Cough—Ethinyl Estradiol—osteoporosis	0.00131	0.00157	CcSEcCtD
Fluocinolone Acetonide—Upper respiratory tract infection—Estradiol—osteoporosis	0.0013	0.00157	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Estropipate—osteoporosis	0.0013	0.00157	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00129	0.00155	CcSEcCtD
Fluocinolone Acetonide—Pain—Estropipate—osteoporosis	0.00129	0.00155	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Zoledronate—osteoporosis	0.00129	0.00155	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Etidronic acid—osteoporosis	0.00128	0.00155	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Zoledronate—osteoporosis	0.00128	0.00154	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.00128	0.00839	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Risedronate—osteoporosis	0.00127	0.00153	CcSEcCtD
Fluocinolone Acetonide—Pain—Alendronate—osteoporosis	0.00127	0.00153	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Zoledronate—osteoporosis	0.00127	0.00153	CcSEcCtD
Fluocinolone Acetonide—Erythema—Zoledronate—osteoporosis	0.00127	0.00153	CcSEcCtD
Fluocinolone Acetonide—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.00126	0.00152	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00126	0.00152	CcSEcCtD
Fluocinolone Acetonide—Infestation NOS—Estradiol—osteoporosis	0.00125	0.00151	CcSEcCtD
Fluocinolone Acetonide—Infestation—Estradiol—osteoporosis	0.00125	0.00151	CcSEcCtD
Fluocinolone Acetonide—Pain—Raloxifene—osteoporosis	0.00125	0.0015	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00125	0.0015	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Risedronate—osteoporosis	0.00124	0.0015	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Zoledronate—osteoporosis	0.00124	0.00149	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Conjugated Estrogens—osteoporosis	0.00124	0.00149	CcSEcCtD
Fluocinolone Acetonide—Pain—Ibandronate—osteoporosis	0.00124	0.00149	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Etidronic acid—osteoporosis	0.00123	0.00148	CcSEcCtD
Fluocinolone Acetonide—Mental disorder—Conjugated Estrogens—osteoporosis	0.00123	0.00148	CcSEcCtD
Fluocinolone Acetonide—Back pain—Zoledronate—osteoporosis	0.00123	0.00148	CcSEcCtD
Fluocinolone Acetonide—Oedema—Ethinyl Estradiol—osteoporosis	0.00122	0.00147	CcSEcCtD
Fluocinolone Acetonide—Erythema—Conjugated Estrogens—osteoporosis	0.00122	0.00147	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Conjugated Estrogens—osteoporosis	0.00122	0.00147	CcSEcCtD
Fluocinolone Acetonide—Infection—Ethinyl Estradiol—osteoporosis	0.00121	0.00146	CcSEcCtD
Fluocinolone Acetonide—Cough—Pamidronate—osteoporosis	0.00121	0.00146	CcSEcCtD
Fluocinolone Acetonide—Pain—Calcitriol—osteoporosis	0.00121	0.00146	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—AGE/RAGE pathway—IRS1—osteoporosis	0.0012	0.00792	CbGpPWpGaD
Fluocinolone Acetonide—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.0012	0.00144	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Conjugated Estrogens—osteoporosis	0.0012	0.00144	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Zoledronate—osteoporosis	0.00119	0.00144	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Etidronic acid—osteoporosis	0.00119	0.00144	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Estropipate—osteoporosis	0.00119	0.00144	CcSEcCtD
Fluocinolone Acetonide—Infection—Risedronate—osteoporosis	0.00118	0.00143	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Pamidronate—osteoporosis	0.00118	0.00142	CcSEcCtD
Fluocinolone Acetonide—Back pain—Conjugated Estrogens—osteoporosis	0.00118	0.00142	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Alendronate—osteoporosis	0.00117	0.00141	CcSEcCtD
Fluocinolone Acetonide—Sinusitis—Estradiol—osteoporosis	0.00117	0.00141	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Risedronate—osteoporosis	0.00117	0.00141	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Raloxifene—osteoporosis	0.00115	0.00139	CcSEcCtD
Fluocinolone Acetonide—Vision blurred—Conjugated Estrogens—osteoporosis	0.00115	0.00139	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—WNT1—osteoporosis	0.00114	0.00753	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Ibandronate—osteoporosis	0.00114	0.00138	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.00114	0.0075	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—p38 MAPK Signaling Pathway—MYC—osteoporosis	0.00114	0.00749	CbGpPWpGaD
Fluocinolone Acetonide—Vertigo—Zoledronate—osteoporosis	0.00114	0.00137	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.00113	0.00747	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—CAP1—osteoporosis	0.00113	0.00745	CbGpPWpGaD
Fluocinolone Acetonide—Oedema—Pamidronate—osteoporosis	0.00113	0.00136	CcSEcCtD
Fluocinolone Acetonide—Infection—Pamidronate—osteoporosis	0.00112	0.00136	CcSEcCtD
Fluocinolone Acetonide—Rhinitis—Estradiol—osteoporosis	0.00112	0.00135	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00112	0.00737	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Calcitriol—osteoporosis	0.00112	0.00135	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Estropipate—osteoporosis	0.00111	0.00134	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Pamidronate—osteoporosis	0.00111	0.00134	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Etidronic acid—osteoporosis	0.00111	0.00133	CcSEcCtD
Fluocinolone Acetonide—Cough—Zoledronate—osteoporosis	0.00111	0.00133	CcSEcCtD
Fluocinolone Acetonide—Connective tissue disorder—Estradiol—osteoporosis	0.0011	0.00133	CcSEcCtD
Fluocinolone Acetonide—Rash—Etidronic acid—osteoporosis	0.0011	0.00132	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Etidronic acid—osteoporosis	0.0011	0.00132	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Conjugated Estrogens—osteoporosis	0.0011	0.00132	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Alendronate—osteoporosis	0.00109	0.00132	CcSEcCtD
Fluocinolone Acetonide—Headache—Etidronic acid—osteoporosis	0.00109	0.00131	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.00109	0.00717	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00109	0.00131	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.00108	0.00711	CbGpPWpGaD
Fluocinolone Acetonide—Visual impairment—Estradiol—osteoporosis	0.00108	0.0013	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Zoledronate—osteoporosis	0.00108	0.0013	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Estropipate—osteoporosis	0.00107	0.00128	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Ibandronate—osteoporosis	0.00106	0.00128	CcSEcCtD
Fluocinolone Acetonide—Cough—Conjugated Estrogens—osteoporosis	0.00106	0.00128	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—TNF—osteoporosis	0.00106	0.007	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00105	0.00127	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Alendronate—osteoporosis	0.00105	0.00127	CcSEcCtD
Fluocinolone Acetonide—Eye disorder—Estradiol—osteoporosis	0.00105	0.00126	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Calcitriol—osteoporosis	0.00104	0.00126	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Conjugated Estrogens—osteoporosis	0.00104	0.00125	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—BMP2—osteoporosis	0.00104	0.00681	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Etidronic acid—osteoporosis	0.00103	0.00125	CcSEcCtD
Fluocinolone Acetonide—Oedema—Zoledronate—osteoporosis	0.00103	0.00125	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00103	0.00124	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Estropipate—osteoporosis	0.00103	0.00124	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—FGA—osteoporosis	0.00103	0.00677	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Risedronate—osteoporosis	0.00103	0.00124	CcSEcCtD
Fluocinolone Acetonide—Infection—Zoledronate—osteoporosis	0.00103	0.00124	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Ibandronate—osteoporosis	0.00102	0.00123	CcSEcCtD
Fluocinolone Acetonide—Pain—Risedronate—osteoporosis	0.00102	0.00123	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Alendronate—osteoporosis	0.00102	0.00122	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Zoledronate—osteoporosis	0.00101	0.00122	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	0.00101	0.00666	CbGpPWpGaD
Fluocinolone Acetonide—Mediastinal disorder—Estradiol—osteoporosis	0.00101	0.00122	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Calcitriol—osteoporosis	0.001	0.00121	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Raloxifene—osteoporosis	0.000999	0.0012	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Estropipate—osteoporosis	0.000997	0.0012	CcSEcCtD
Fluocinolone Acetonide—Oedema—Conjugated Estrogens—osteoporosis	0.000996	0.0012	CcSEcCtD
Fluocinolone Acetonide—Alopecia—Estradiol—osteoporosis	0.000991	0.00119	CcSEcCtD
Fluocinolone Acetonide—Infection—Conjugated Estrogens—osteoporosis	0.000989	0.00119	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Ibandronate—osteoporosis	0.000989	0.00119	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Opioid Signalling—POMC—osteoporosis	0.000984	0.00647	CbGpPWpGaD
Fluocinolone Acetonide—Mental disorder—Estradiol—osteoporosis	0.000983	0.00118	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Alendronate—osteoporosis	0.000982	0.00118	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000978	0.00118	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000977	0.00118	CcSEcCtD
Fluocinolone Acetonide—Erythema—Estradiol—osteoporosis	0.000977	0.00118	CcSEcCtD
Fluocinolone Acetonide—Malnutrition—Estradiol—osteoporosis	0.000977	0.00118	CcSEcCtD
Fluocinolone Acetonide—Pain—Pamidronate—osteoporosis	0.000968	0.00117	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Calcitriol—osteoporosis	0.000968	0.00117	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000966	0.00116	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Raloxifene—osteoporosis	0.000965	0.00116	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Estropipate—osteoporosis	0.000958	0.00115	CcSEcCtD
Fluocinolone Acetonide—Dysgeusia—Estradiol—osteoporosis	0.000956	0.00115	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Ibandronate—osteoporosis	0.000956	0.00115	CcSEcCtD
Fluocinolone Acetonide—Rash—Estropipate—osteoporosis	0.00095	0.00114	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Estropipate—osteoporosis	0.000949	0.00114	CcSEcCtD
Fluocinolone Acetonide—Back pain—Estradiol—osteoporosis	0.000945	0.00114	CcSEcCtD
Fluocinolone Acetonide—Headache—Estropipate—osteoporosis	0.000944	0.00114	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Alendronate—osteoporosis	0.000944	0.00114	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000942	0.00114	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Risedronate—osteoporosis	0.000942	0.00113	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—FGB—osteoporosis	0.000936	0.00616	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Alendronate—osteoporosis	0.000936	0.00113	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Alendronate—osteoporosis	0.000935	0.00113	CcSEcCtD
Fluocinolone Acetonide—Headache—Alendronate—osteoporosis	0.00093	0.00112	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Raloxifene—osteoporosis	0.000928	0.00112	CcSEcCtD
Fluocinolone Acetonide—Rash—Raloxifene—osteoporosis	0.000921	0.00111	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Raloxifene—osteoporosis	0.00092	0.00111	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Ibandronate—osteoporosis	0.000919	0.00111	CcSEcCtD
Fluocinolone Acetonide—Headache—Raloxifene—osteoporosis	0.000915	0.0011	CcSEcCtD
Fluocinolone Acetonide—Rash—Ibandronate—osteoporosis	0.000911	0.0011	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Ibandronate—osteoporosis	0.000911	0.0011	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000908	0.00597	CbGpPWpGaD
Fluocinolone Acetonide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000907	0.00109	CcSEcCtD
Fluocinolone Acetonide—Headache—Ibandronate—osteoporosis	0.000905	0.00109	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—MGLL—osteoporosis	0.0009	0.00592	CbGpPWpGaD
Fluocinolone Acetonide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.0009	0.00108	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Calcitriol—osteoporosis	0.0009	0.00108	CcSEcCtD
Fluocinolone Acetonide—Nausea—Estropipate—osteoporosis	0.000895	0.00108	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Pamidronate—osteoporosis	0.000895	0.00108	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000893	0.00108	CcSEcCtD
Fluocinolone Acetonide—Rash—Calcitriol—osteoporosis	0.000892	0.00107	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Calcitriol—osteoporosis	0.000891	0.00107	CcSEcCtD
Fluocinolone Acetonide—Headache—Calcitriol—osteoporosis	0.000886	0.00107	CcSEcCtD
Fluocinolone Acetonide—Pain—Zoledronate—osteoporosis	0.000885	0.00107	CcSEcCtD
Fluocinolone Acetonide—Nausea—Alendronate—osteoporosis	0.000882	0.00106	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Risedronate—osteoporosis	0.000878	0.00106	CcSEcCtD
Fluocinolone Acetonide—Vertigo—Estradiol—osteoporosis	0.000877	0.00106	CcSEcCtD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—ESR1—osteoporosis	0.000869	0.00572	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Raloxifene—osteoporosis	0.000867	0.00104	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000864	0.00104	CcSEcCtD
Fluocinolone Acetonide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00086	0.00104	CcSEcCtD
Fluocinolone Acetonide—Nausea—Ibandronate—osteoporosis	0.000859	0.00103	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Transcription factor regulation in adipogenesis—IL6—osteoporosis	0.000858	0.00565	CbGpPWpGaD
Fluocinolone Acetonide—Cough—Estradiol—osteoporosis	0.000852	0.00103	CcSEcCtD
Fluocinolone Acetonide—Pain—Conjugated Estrogens—osteoporosis	0.000852	0.00103	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Risedronate—osteoporosis	0.000843	0.00102	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000841	0.00553	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Calcitriol—osteoporosis	0.00084	0.00101	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000836	0.00101	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Pamidronate—osteoporosis	0.000834	0.001	CcSEcCtD
Fluocinolone Acetonide—Arthralgia—Estradiol—osteoporosis	0.000831	0.001	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—ANXA2—osteoporosis	0.000823	0.00542	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—PLEK—osteoporosis	0.000823	0.00542	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000819	0.00539	CbGpPWpGaD
Fluocinolone Acetonide—Body temperature increased—Zoledronate—osteoporosis	0.000818	0.000985	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Risedronate—osteoporosis	0.000815	0.000982	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000808	0.000973	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Pamidronate—osteoporosis	0.000801	0.000965	CcSEcCtD
Fluocinolone Acetonide—Oedema—Estradiol—osteoporosis	0.000797	0.00096	CcSEcCtD
Fluocinolone Acetonide—Infection—Estradiol—osteoporosis	0.000792	0.000954	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Risedronate—osteoporosis	0.000788	0.000949	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000787	0.000948	CcSEcCtD
Fluocinolone Acetonide—Nervous system disorder—Estradiol—osteoporosis	0.000782	0.000942	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000777	0.000936	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Pamidronate—osteoporosis	0.000775	0.000933	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	0.000774	0.00509	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Ethinyl Estradiol—osteoporosis	0.00077	0.000928	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00077	0.000927	CcSEcCtD
Fluocinolone Acetonide—Headache—Ethinyl Estradiol—osteoporosis	0.000765	0.000922	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Zoledronate—osteoporosis	0.000762	0.000918	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Risedronate—osteoporosis	0.000757	0.000912	CcSEcCtD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000755	0.00497	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Risedronate—osteoporosis	0.000751	0.000905	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Risedronate—osteoporosis	0.00075	0.000904	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Pamidronate—osteoporosis	0.000749	0.000902	CcSEcCtD
Fluocinolone Acetonide—Headache—Risedronate—osteoporosis	0.000746	0.000899	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000734	0.000884	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Zoledronate—osteoporosis	0.000732	0.000881	CcSEcCtD
Fluocinolone Acetonide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000726	0.000875	CcSEcCtD
Fluocinolone Acetonide—Nausea—Ethinyl Estradiol—osteoporosis	0.000726	0.000874	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Pamidronate—osteoporosis	0.00072	0.000867	CcSEcCtD
Fluocinolone Acetonide—Rash—Pamidronate—osteoporosis	0.000714	0.00086	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Pamidronate—osteoporosis	0.000713	0.000859	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TLN1—osteoporosis	0.00071	0.00467	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Pamidronate—osteoporosis	0.000709	0.000854	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Zoledronate—osteoporosis	0.000708	0.000852	CcSEcCtD
Fluocinolone Acetonide—Nausea—Risedronate—osteoporosis	0.000708	0.000852	CcSEcCtD
Fluocinolone Acetonide—Pruritus—Conjugated Estrogens—osteoporosis	0.000705	0.000849	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—VCL—osteoporosis	0.0007	0.00461	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—POMC—osteoporosis	0.000689	0.00453	CbGpPWpGaD
Fluocinolone Acetonide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000688	0.000829	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Zoledronate—osteoporosis	0.000684	0.000824	CcSEcCtD
Fluocinolone Acetonide—Pain—Estradiol—osteoporosis	0.000682	0.000821	CcSEcCtD
Fluocinolone Acetonide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000681	0.000821	CcSEcCtD
Fluocinolone Acetonide—Nausea—Pamidronate—osteoporosis	0.000673	0.00081	CcSEcCtD
Fluocinolone Acetonide—Dizziness—Conjugated Estrogens—osteoporosis	0.000659	0.000793	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Zoledronate—osteoporosis	0.000658	0.000792	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000655	0.00431	CbGpPWpGaD
Fluocinolone Acetonide—Rash—Zoledronate—osteoporosis	0.000652	0.000786	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Zoledronate—osteoporosis	0.000652	0.000785	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTH1R—osteoporosis	0.00065	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CALCR—osteoporosis	0.00065	0.00428	CbGpPWpGaD
Fluocinolone Acetonide—Headache—Zoledronate—osteoporosis	0.000648	0.000781	CcSEcCtD
Fluocinolone Acetonide—Vomiting—Conjugated Estrogens—osteoporosis	0.000633	0.000763	CcSEcCtD
Fluocinolone Acetonide—Body temperature increased—Estradiol—osteoporosis	0.00063	0.000759	CcSEcCtD
Fluocinolone Acetonide—Rash—Conjugated Estrogens—osteoporosis	0.000628	0.000756	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Conjugated Estrogens—osteoporosis	0.000627	0.000756	CcSEcCtD
Fluocinolone Acetonide—Headache—Conjugated Estrogens—osteoporosis	0.000624	0.000752	CcSEcCtD
Fluocinolone Acetonide—Nausea—Zoledronate—osteoporosis	0.000614	0.00074	CcSEcCtD
Fluocinolone Acetonide—Nausea—Conjugated Estrogens—osteoporosis	0.000592	0.000713	CcSEcCtD
Fluocinolone Acetonide—Hypersensitivity—Estradiol—osteoporosis	0.000587	0.000707	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—RAP1A—osteoporosis	0.000585	0.00385	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IRS2—osteoporosis	0.000567	0.00373	CbGpPWpGaD
Fluocinolone Acetonide—Pruritus—Estradiol—osteoporosis	0.000564	0.000679	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000557	0.00366	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—LEP—osteoporosis	0.000555	0.00365	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.00055	0.00362	CbGpPWpGaD
Fluocinolone Acetonide—Diarrhoea—Estradiol—osteoporosis	0.000545	0.000657	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—FGA—osteoporosis	0.000531	0.00349	CbGpPWpGaD
Fluocinolone Acetonide—Dizziness—Estradiol—osteoporosis	0.000527	0.000635	CcSEcCtD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—MGLL—osteoporosis	0.000517	0.0034	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—FDPS—osteoporosis	0.000508	0.00334	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PKM—osteoporosis	0.000508	0.00334	CbGpPWpGaD
Fluocinolone Acetonide—Vomiting—Estradiol—osteoporosis	0.000507	0.00061	CcSEcCtD
Fluocinolone Acetonide—Rash—Estradiol—osteoporosis	0.000503	0.000605	CcSEcCtD
Fluocinolone Acetonide—Dermatitis—Estradiol—osteoporosis	0.000502	0.000605	CcSEcCtD
Fluocinolone Acetonide—Headache—Estradiol—osteoporosis	0.000499	0.000601	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IRS1—osteoporosis	0.000495	0.00326	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—FGB—osteoporosis	0.000483	0.00318	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PGLS—osteoporosis	0.000482	0.00317	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GPD2—osteoporosis	0.000482	0.00317	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000476	0.00313	CbGpPWpGaD
Fluocinolone Acetonide—Nausea—Estradiol—osteoporosis	0.000473	0.00057	CcSEcCtD
Fluocinolone Acetonide—NR3C1—Endoderm Differentiation—TGFB1—osteoporosis	0.000462	0.00304	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IGF1—osteoporosis	0.000459	0.00302	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—MYC—osteoporosis	0.000452	0.00297	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—TGFB1—osteoporosis	0.000451	0.00297	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PNP—osteoporosis	0.00044	0.0029	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ATIC—osteoporosis	0.00044	0.0029	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SOST—osteoporosis	0.000425	0.00279	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—IGF1—osteoporosis	0.000424	0.00279	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	0.000402	0.00265	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000402	0.00264	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—PDGFR-beta signaling pathway—MYC—osteoporosis	0.000402	0.00264	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—U2AF1—osteoporosis	0.000401	0.00264	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CALCR—osteoporosis	0.000384	0.00253	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTH1R—osteoporosis	0.000384	0.00253	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—OXCT1—osteoporosis	0.000375	0.00246	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CA2—osteoporosis	0.000375	0.00246	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—MGLL—osteoporosis	0.000365	0.0024	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000344	0.00226	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTH—osteoporosis	0.000342	0.00225	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—AP-1 transcription factor network—IL6—osteoporosis	0.00034	0.00224	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CNR2—osteoporosis	0.000333	0.00219	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR2—osteoporosis	0.000319	0.0021	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—WNT1—osteoporosis	0.000313	0.00206	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—IDH2—osteoporosis	0.00031	0.00204	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000306	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MGLL—osteoporosis	0.000305	0.00201	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Glucocorticoid receptor regulatory network—IL6—osteoporosis	0.0003	0.00197	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—RPL24—osteoporosis	0.000298	0.00196	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—LRP5—osteoporosis	0.000298	0.00196	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP27A1—osteoporosis	0.000292	0.00192	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	0.000286	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	0.000286	0.00188	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—LRP6—osteoporosis	0.000285	0.00187	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ACP5—osteoporosis	0.000284	0.00187	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—PTHLH—osteoporosis	0.000283	0.00186	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	0.00028	0.00184	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TGFB1—osteoporosis	0.000275	0.00181	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	0.000267	0.00175	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—TPI1—osteoporosis	0.000264	0.00174	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—TNF—osteoporosis	0.000257	0.00169	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	0.000254	0.00167	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—VDR—osteoporosis	0.000253	0.00167	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—CALCA—osteoporosis	0.000249	0.00164	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—P4HB—osteoporosis	0.000248	0.00163	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GAPDH—osteoporosis	0.000244	0.0016	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TLN1—osteoporosis	0.000241	0.00158	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—RAP1A—osteoporosis	0.000237	0.00156	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—TNF—osteoporosis	0.000222	0.00146	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—IGF1—osteoporosis	0.000219	0.00144	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—P4HB—osteoporosis	0.000207	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Adipogenesis—IL6—osteoporosis	0.000207	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—osteoporosis	0.000207	0.00136	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTH—osteoporosis	0.000202	0.00133	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—RAP1A—osteoporosis	0.000198	0.0013	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CNR2—osteoporosis	0.000197	0.00129	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—ESR1—osteoporosis	0.000193	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—NFATC1—osteoporosis	0.000193	0.00127	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—DKK1—osteoporosis	0.000192	0.00126	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ENO1—osteoporosis	0.000192	0.00126	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSMA2—osteoporosis	0.000189	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—PSMA5—osteoporosis	0.000189	0.00124	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—WNT1—osteoporosis	0.000185	0.00122	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FGA—osteoporosis	0.00018	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—SIDS Susceptibility Pathways—IL6—osteoporosis	0.000179	0.00118	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—ADCY5—osteoporosis	0.000177	0.00117	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSMA2—osteoporosis	0.000172	0.00113	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—PSMA5—osteoporosis	0.000172	0.00113	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PTHLH—osteoporosis	0.000167	0.0011	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—BMP2—osteoporosis	0.000167	0.0011	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—FGB—osteoporosis	0.000164	0.00108	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSMA2—osteoporosis	0.000158	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—PSMA5—osteoporosis	0.000158	0.00104	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR2—osteoporosis	0.000154	0.00101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—CYP19A1—osteoporosis	0.000153	0.00101	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—CALCA—osteoporosis	0.000147	0.000968	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—KL—osteoporosis	0.000134	0.000879	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Hemostasis—TGFB1—osteoporosis	0.000131	0.000862	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—POMC—osteoporosis	0.00013	0.000858	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6R—osteoporosis	0.000127	0.000837	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—ADCY5—osteoporosis	0.000125	0.000824	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—GPX1—osteoporosis	0.000125	0.000821	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—VDR—osteoporosis	0.000122	0.000802	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—MTHFR—osteoporosis	0.000115	0.000758	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ADCY5—osteoporosis	0.000105	0.000689	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—SPP1—osteoporosis	0.000101	0.000666	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Generic Transcription Pathway—MYC—osteoporosis	0.000101	0.000662	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—ESR1—osteoporosis	9.32e-05	0.000613	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Metabolism—POMC—osteoporosis	9.21e-05	0.000606	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IRS2—osteoporosis	9.16e-05	0.000603	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—LEP—osteoporosis	8.97e-05	0.00059	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—ESR1—osteoporosis	8.56e-05	0.000563	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IRS1—osteoporosis	8e-05	0.000526	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—POMC—osteoporosis	7.7e-05	0.000507	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6R—osteoporosis	7.51e-05	0.000494	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IGF1—osteoporosis	7.41e-05	0.000487	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling by GPCR—IL6—osteoporosis	5.67e-05	0.000373	CbGpPWpGaD
Fluocinolone Acetonide—NR3C1—Gene Expression—MYC—osteoporosis	4.85e-05	0.000319	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—MYC—osteoporosis	4.45e-05	0.000293	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—TGFB1—osteoporosis	4.44e-05	0.000292	CbGpPWpGaD
Fluocinolone Acetonide—PLA2G4A—Signaling Pathways—IL6—osteoporosis	3.35e-05	0.00022	CbGpPWpGaD
